Multiple Dose

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	16

2. 筋萎縮性側索硬化症

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

trials per page:

Showing 1 to 10 of 16 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05633459 (ClinicalTrials.gov)	December 16, 2022	21/11/2022	A Study Evaluating the Safety and Tolerability of QRL-201 in ALS	A Multi-Center, Randomized, Double-Blind Placebo Controlled Multiple-Ascending DoseStudy to Evaluate ...	Amyotrophic Lateral Sclerosis	Drug: QRL-201 - Dose1;Drug: QRL-201 - Dose2;Drug: QRL-201 - Dose3;Drug: QRL-201 - Dose4;Drug: QRL-20 ...	QurAlis Corporation	NULL	Recruiting	18 Years	80 Years	All	64	Phase 1	Canada
2	NCT04948645 (ClinicalTrials.gov)	September 22, 2021	23/6/2021	A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amy ...	A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Pharmacokin ...	ALS;Amyotrophic Lateral Sclerosis	Drug: ABBV-CLS-7262;Drug: Placebo	Calico Life Sciences LLC	AbbVie	Active, not recruiting	18 Years	80 Years	All	31	Phase 1	United States;Canada
3	NCT04494256 (ClinicalTrials.gov)	September 28, 2020	30/7/2020	A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Particip ...	A Phase 1/2 Multiple-Ascending-DoseStudy With a Long-Term Open-Label Extension to Assess the Safety, ...	Amyotrophic Lateral Sclerosis	Drug: BIIB105;Drug: Placebo	Biogen	NULL	Recruiting	18 Years	N/A	All	98	Phase 1/Phase 2	United States;Canada;Italy;Netherlands
4	NCT04066244 (ClinicalTrials.gov)	December 30, 2019	21/8/2019	Study of Safety and of the Mechanism of BLZ945 in ALS Patients	An Open-label, Adaptive Design Study in Patients With Amyotrophic Lateral Sclerosis (ALS) to Charact ...	Amyotrophic Lateral Sclerosis	Drug: BLZ945	Novartis Pharmaceuticals	NULL	Recruiting	18 Years	N/A	All	56	Phase 2	United States;Finland;Sweden
5	EUCTR2019-000826-22-FI (EUCTR)	05/11/2019	18/09/2019	Study of safety and of the mechanism of BLZ945 in amyotrophic lateral sclerosis (ALS) patients.	An open-label, adaptive design study in patients with amyotrophic lateral sclerosis (ALS) to charact ...	Amyotrophic lateral sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term ...	Product Code: BLZ945 INN or Proposed INN: Not yet defined Other descriptive name: BLZ945 Product Code: ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 2	United States;Finland;Sweden
6	EUCTR2019-000826-22-SE (EUCTR)	17/09/2019	02/08/2019	Study of safety and of the mechanism of BLZ945 in amyotrophic lateral sclerosis (ALS) patients.	An open-label, adaptive design study in patients with amyotrophic lateral sclerosis (ALS) to charact ...	Amyotrophic lateral sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term ...	Product Code: BLZ945 INN or Proposed INN: Not yet defined Other descriptive name: BLZ945 Product Code: ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 2	United States;Finland;Sweden
7	NCT03626012 (ClinicalTrials.gov)	September 10, 2018	7/8/2018	A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-A ...	A Phase 1 Multiple-Ascending-DoseStudy to Assess the Safety, Tolerability, and Pharmacokinetics of B ...	Amyotrophic Lateral Sclerosis	Drug: BIIB078;Drug: Placebo	Biogen	NULL	Completed	18 Years	N/A	All	106	Phase 1	United States;Canada;Ireland;Netherlands;Switzerland;United Kingdom
8	NCT03520517 (ClinicalTrials.gov)	February 2, 2018	17/4/2018	Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS	Open-Label Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of BHV-0223 ...	Amyotrophic Lateral Sclerosis;ALS;Lou Gehrig Disease;Lou Gehrig's Disease;Lou-Gehrigs Disease;Motor ...	Drug: BHV-0223	Biohaven Pharmaceuticals, Inc.	Cognitive Research Corporation	Completed	18 Years	N/A	All	22	Phase 1	United States
9	NCT03049046 (ClinicalTrials.gov)	April 7, 2017	3/2/2017	CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS	Protocol CC100B. CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS	Amyotrophic Lateral Sclerosis	Drug: CC100;Drug: Placebos	Chemigen, LLC	NULL	Recruiting	18 Years	64 Years	All	21	Phase 1	United States
10	NCT02870634 (ClinicalTrials.gov)	November 16, 2016	10/8/2016	Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND	A Phase 1 Single and Multiple DoseEscalation and Pharmacokinetic Study of Cu(II)ATSM Administered Or ...	Amyotrophic Lateral Sclerosis;Motor Neuron Disease	Drug: Cu(II)ATSM	Collaborative Medicinal Development Pty Limited	NULL	Completed	18 Years	75 Years	All	50	Phase 1	Australia

First Previous1 2Next Last